title: Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines.
authors.affiliation: Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, De Pintelaan 185, 9000 Gent, Belgium. Isabelle.Colle@Ugent.be
authors.forename: I
authors.initials: I
authors.lastname: Colle
authors.forename: M
authors.initials: M
authors.lastname: Adler
authors.forename: R
authors.initials: R
authors.lastname: Brenard
authors.forename: J
authors.initials: J
authors.lastname: Henrion
authors.forename: P
authors.initials: P
authors.lastname: Langlet
authors.forename: P
authors.initials: P
authors.lastname: Michielsen
authors.forename: H
authors.initials: H
authors.lastname: Orlent
authors.forename: H
authors.initials: H
authors.lastname: Reynaert
authors.forename: D
authors.initials: D
authors.lastname: Sprengers
authors.forename: P
authors.initials: P
authors.lastname: Stärkel
authors.forename: P
authors.initials: P
authors.lastname: Van Damme
authors.forename: C
authors.initials: C
authors.lastname: Verslype
authors.forename: J
authors.initials: J
authors.lastname: Delwaide
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D008403:Mass Screening; D009705:Nucleosides / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D014611:Vaccination
chemical_list: D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009705:Nucleosides; D063065:Organophosphonates; D011744:Pyrimidinones; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D000077712:Telbivudine; D019259:Lamivudine; D011092:Polyethylene Glycols; C413685:entecavir; D006147:Guanine; C053001:adefovir; D000225:Adenine; C100416:peginterferon alfa-2a; D013936:Thymidine